Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophosphamide and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65.

Trial Profile

Open, Multicentral, Randomised Phase II Study of Allogene Stem Cell Transplantation After Pretreatment With Fludarabin, Busulfan, Cyclophosphamide and GVHD-Prophylaxis With or Without Rituximab in Patients With Recidivation of High Grade Non-Hodgkin's Lymphoma in Special Risk Situation in the Age of 18 - 65.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2014

At a glance

  • Drugs Rituximab (Primary) ; Antineoplastics; Antithymocyte globulin; Busulfan; Cyclophosphamide; Fludarabine; Immunosuppressants; Mycophenolate mofetil; Tacrolimus
  • Indications Graft-versus-host disease; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Amgen; Astellas Pharma; Roche
  • Most Recent Events

    • 28 May 2014 Status changed from active, no longer recruiting to completed.
    • 09 May 2014 Primary endpoint 'Acute-graft-versus-host-disease' has not been met.
    • 09 May 2014 Results published in the Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top